Drug developers have long needed to diversify clinical trials to improve the safety, efficacy, and adoption of new therapies among historically underrepresented groups. “This isn’t new for us,” says Giovanni Caforio, CEO of Bristol Myers Squibb, which makes treatments for everything from cancer to HIV/AIDS. But BMS made big strides this year. Now, 58% of its U.S. trial sites (compared with a 25% goal) are located in communities that have at least a 30% nonwhite population. It also increased nonwhite-patient recruitment by 22%. There’s more work to be done, but BMS’s sustained focus on diversity is yielding real progress.
More from TIME
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
- Taylor Swift Is TIME's 2023 Person of the Year
- Meet the Nation Builders
- Why Cell Phone Reception Is Getting Worse
- Column: It's Time to Scrap the Abraham Accords
- Israeli Family Celebrates Release of Hostage Grandmother
- In a New Movie, Beyoncé Finds Freedom
- The Top 100 Photos of 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time